Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Report
May 20, 2011
Formulary Advantages in Hepatitis C: Despite the near certainty of emerging oral protease inhibitors, pharmacy directors remain unsure of the…
According to the American Liver Foundation, 4 million Americans, or 1.8% of the population, are or have been infected with the hepatitis C virus. Approximately 70% of infected persons will develop a c…
Report
March 31, 2011
Formulary Advantages in Therapies for Multiple Sclerosis: Health plans await the arrival of orally administered therapies to compete with existing brands
With increased diagnosis rates and higher drug prices for multiple sclerosis (MS), U.S. health plans have grown more focused on their coverage of and spending on MS therapies. Partly because of the pr…
Report
March 18, 2011
Formulary Advantages in Dyslipidemia: Will outcomes data dominate the reimbursement landscape for dyslipidemia?
The significant impact of cardiovascular disease on human morbidity and mortality alongside the proven efficacy of many lipid-modifying therapies drives both the aggressive treatment of dyslipidemia b…
